DEANE F MOSHER, MD
Osteopathic Medicine at Highland Ave, Madison, WI
License number
Wisconsin 20628
Category
Osteopathic Medicine
Type
Hematology
Address
Address
600 Highland Ave, Madison, WI 53792
Phone
(608) 265-1700
(608) 266-6020 (Fax)
(608) 266-6020 (Fax)
Professional information
P-Selectin Associated With Eosinophils As A Marker For Asthma And Correlating With B-1 Integrin Activation
US Patent:
2013025, Sep 26, 2013
Filed:
May 20, 2013
Appl. No.:
13/898047
Inventors:
Deane F. Mosher - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
G01N 33/68
US Classification:
435 792, 435 71
Abstract:
Methods are provided for the detection of P-selectin associated with eosinophils and for the use of P-selectin as a biological marker for asthma. In one embodiment, the present invention relates to methods for detecting P-selectin in a sample containing eosinophils and quantifying the total number of eosinophils. In another embodiment, the present invention relates a method for determining the proportion of eosinophils that are P-selectin positive and positive for at least partially activated β-1 integrin. In yet another embodiment, the present invention relates to kits for the detection of P-selectin and for the detection of eosinophils that are both P-selectin positive and positive for at least partially activated β-1 integrin. In still yet another embodiment, the invention relates to a method for monitoring a biological condition.
P-Selectin Associated With Eosinophils As A Marker For Asthma And Correlating With B-1 Integrin Activation
US Patent:
2009006, Mar 5, 2009
Filed:
May 29, 2008
Appl. No.:
12/129317
Inventors:
Mats W. Johansson - Madison WI, US
Deane F. Mosher - Madison WI, US
Deane F. Mosher - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
G01N 33/53, C12Q 1/02, G01N 33/68, G01N 33/573
US Classification:
435 724, 435 29, 435 792, 436 86
Abstract:
Methods are provided for the detection of P-selectin associated with eosinophils and for the use of P-selectin as a biological marker for asthma. In one embodiment, the present invention relates to methods for detecting P-selectin in a sample containing eosinophils and quantifying the total number of eosinophils. In another embodiment, the present invention relates a method for determining the proportion of eosinophils that are P-selectin positive and positive for at least partially activated β-1 integrin. In yet another embodiment, the present invention relates to kits for the detection of P-selectin and for the detection of eosinophils that are both P-selectin positive and positive for at least partially activated β-1 integrin. In still yet another embodiment, the invention relates to a method for monitoring a biological condition.
P-Selectin Associated With Eosinophils As A Marker For Asthma And Correlating With B-1 Integrin Activation
US Patent:
2011017, Jul 14, 2011
Filed:
Mar 29, 2011
Appl. No.:
13/074822
Inventors:
Mats W. Johansson - Madison WI, US
Deane F. Mosher - Madison WI, US
Deane F. Mosher - Madison WI, US
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION - Madison WI
International Classification:
G01N 33/53, C12Q 1/06, G01N 33/68
US Classification:
435 724, 435 39, 436 86, 435 792, 435 721
Abstract:
Methods are provided for the detection of P-selectin associated with eosinophils and for the use of P-selectin as a biological marker for asthma. In one embodiment, the present invention relates to methods for detecting P-selectin in a sample containing eosinophils and quantifying the total number of eosinophils. In another embodiment, the present invention relates a method for determining the proportion of eosinophils that are P-selectin positive and positive for at least partially activated β-1 integrin. In yet another embodiment, the present invention relates to kits for the detection of P-selectin and for the detection of eosinophils that are both P-selectin positive and positive for at least partially activated β-1 integrin. In still yet another embodiment, the invention relates to a method for monitoring a biological condition.
Use Of Lysophosphatidic Acids To Enhance Fibronectin Binding
US Patent:
5480877, Jan 2, 1996
Filed:
Apr 14, 1995
Appl. No.:
8/422738
Inventors:
Deane F. Mosher - Madison WI
William J. Checovich - Madison WI
William J. Checovich - Madison WI
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
A61K 3166
US Classification:
514134
Abstract:
Lysophosphatidic acids are used to enhance fibronectin binding. This assists in the process of wound healing. The acids are exogenously supplied. In one aspect, a kit is provided containing a skin salve that contains the acid or a salt thereof.
Monoclonal Antibody To Thrombospondin And Method For Assaying For And Isolating Thrombospondin
US Patent:
4610960, Sep 9, 1986
Filed:
Dec 21, 1983
Appl. No.:
6/565024
Inventors:
Deane F. Mosher - Madison WI
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
G01N 3353, C12P 2100, A61K 39395, C12N 500
US Classification:
435 7
Abstract:
A monoclonal antibody produced by a hybridoma formed by the fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with thrombospondin. The monoclonal antibody reacts with human, bovine, and canine thrombospondin but not with the thrombospondin present in rabbit serum. The monoclonal antibody is capable of being used to identify human, bovine, and canine thrombospondin in ELISAs and by means of immunohistological techniques and also can be used to isolate such thrombospondin by when employed in immunoisolation techniques.
Fibronectin Purification Vector
US Patent:
5460955, Oct 24, 1995
Filed:
Oct 28, 1993
Appl. No.:
8/145061
Inventors:
Deane F. Mosher - Madison WI
Jane M. Sottile - Madison WI
Jane M. Sottile - Madison WI
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C07K 122, C07K 114, C12N 1509, C12N 1563
US Classification:
435 697
Abstract:
Recombinant protein purification vectors and methods for their use are disclosed. The vectors contain a DNA sequence coding for a gelatin binding region of fibronectin. The vectors express a foreign DNA sequence of interest fused to the fibronectin portion. Secretion signals on the fused product assist the product in being secreted from a production cell. The product can then be purified on a gelatin-containing affinity column and digested with a protease, such as trypsin, to cleave the desired protein from the gelatin binding region. The protein then contains no more than one extraneous amino acid.
Process For Preparation Of Multimeric Plasma Fibronectin
US Patent:
4705751, Nov 10, 1987
Filed:
Dec 28, 1983
Appl. No.:
6/566215
Inventors:
Deane F. Mosher - Madison WI
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
A61K 3702, C07K 1514, C12N 500, C12P 2100
US Classification:
435 68
Abstract:
A method for preparation of multimeric fibronectin. Dimeric fibronectin is treated with guanidine. The dimeric fibronectin so treated is then incubated to allow multimeric fibronectin to form therefrom.
Transglutaminase And Gene Encoding Same
US Patent:
6114119, Sep 5, 2000
Filed:
Aug 29, 1997
Appl. No.:
8/920919
Inventors:
Daniel P. Aeschlimann - Madison WI
Deane F. Mosher - Madison WI
Deane F. Mosher - Madison WI
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
A pair of degenerate oligonucleotide primers can amplify transglutaminase-specific fragments of known transglutaminase genes. The primers are also used to obtain new transglutaminase gene products. The nucleotide sequence of a novel transglutaminase gene (termed TG. sub. X) is presented.
Methods To Make And Use Proteinaceous Material Present In Kinin-Free High Molecular Weight Kininogen
US Patent:
5114413, May 19, 1992
Filed:
Jun 8, 1990
Appl. No.:
7/544133
Inventors:
Deane F. Mosher - Madison WI
Shinji Asakura - Madison WI
Shinji Asakura - Madison WI
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
A61M 532, A61M 2500
US Classification:
604266
Abstract:
Disclosed herein are methods for using a proteinaceous material present in kinin free high molecular weight kininogen to treat surfaces to prevent or minimize adhesion by blood components and/or animal cells. For example, in medical applications, one can treat plastic tubes or other conduits that carry blood to reduce the tendency of the blood to block the conduit. Also disclosed is an improved method of purifying kinin free high molecular weight kininogen.
Fibronectin Purification Vector
US Patent:
5342762, Aug 30, 1994
Filed:
Jan 3, 1991
Appl. No.:
7/637250
Inventors:
Deane F. Mosher - Madison WI
Jane M. Sottile - Madison WI
Jane M. Sottile - Madison WI
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C12N 1511, C12N 1566, C07K 312, C07K 318
US Classification:
435 691
Abstract:
Recombinant protein purification vectors and methods for their use are disclosed. The vectors contain a DNA sequence coding for a gelatin binding region of fibronectin. The vectors express a foreign DNA sequence of interest fused to the fibronectin portion. Secretion signals on the fused product assist the product in being secreted from a production cell. The product can then be purified on a gelatin containing affinity column and digested with a protease such as trypsin to cleave the desired protein from the gelatin binding region. The vectors can also be designed to code for factor XIIIa cross liking sites and to have a chemically reactive cysteine residue.